|
ANKRD13A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.9575010763192E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.47620027313167E-10 |
| Normal-vs-Stage2 |
5.383600E-04 |
| Normal-vs-Stage3 |
2.2425999945952E-08 |
| Normal-vs-Stage4 |
1.716500053206E-09 |
| Stage1-vs-Stage2 |
8.048800E-01 |
| Stage1-vs-Stage3 |
9.954400E-01 |
| Stage1-vs-Stage4 |
2.678400E-01 |
| Stage2-vs-Stage3 |
8.169600E-01 |
| Stage2-vs-Stage4 |
3.562400E-01 |
| Stage3-vs-Stage4 |
3.448600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.053301972893E-11 |
| Normal-vs-AfricanAmerican |
1.189920E-04 |
| Normal-vs-Asian |
1.735500E-03 |
| Caucasian-vs-AfricanAmerican |
7.296600E-01 |
| Caucasian-vs-Asian |
4.736200E-02 |
| AfricanAmerican-vs-Asian |
3.398400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.66300001441999E-09 |
| Normal-vs-Female |
8.78990213948327E-11 |
| Male-vs-Female |
8.530800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.27589999571387E-08 |
| Normal-vs-Age(41-60Yrs) |
2.80980017031141E-10 |
| Normal-vs-Age(61-80Yrs) |
1.25489999502904E-08 |
| Normal-vs-Age(81-100Yrs) |
1.277320E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.100400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.876400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.663400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.910800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.477400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.926600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.670800E-01 |
| Classical-VS-Follicular |
9.005000E-01 |
| Classical-VS-Other |
4.182800E-01 |
| Classical-VS-Normal |
1.98799976480757E-10 |
| Tall-VS-Follicular |
4.627400E-01 |
| Tall-VS-Other |
1.753560E-01 |
| Tall-VS-Normal |
2.633200E-04 |
| Follicular-VS-Other |
2.482200E-01 |
| Follicular-VS-Normal |
6.34269999966186E-07 |
| Other-VS-Normal |
2.208000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.07629527091558E-12 |
| Normal-vs-N1 |
2.24989999997316E-06 |
| N0-vs-N1 |
3.696400E-01 |
|
|
